
SUMMARY: The purpose of this notice is to inform Federal agencies that FTR Bulletin 19–02, pertaining to travel, transportation, and relocation allowances impacted by recent changes to Federal tax law, has been published and is now available online at www.gsa.gov/ftrbulletin.

DATES: Applicability: This notice applies to travel, transportation, and relocation expenses paid on or after January 1, 2018.

FOR FURTHER INFORMATION CONTACT: For clarification of content, please contact Mr. Rick Miller, Office of Government-wide Policy, Office of Asset and Transportation Management, at 202–501–3822, or by email at travelpolicy@gsa.gov. Please cite Notice of FTR Bulletin 19–02.

Dated: November 27, 2018.

Jessica Salmoiraghi, Associate Administrator, Office of Government-wide Policy.

[FR Doc. 2018–26342 Filed 12–3–18; 8:45 am]

BILLING CODE 6820–14–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data Request on Interventions for Substance Use Disorders in Adolescents: A Systematic Review

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submissions.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review of Interventions for Substance Use Disorders in Adolescents: A Systematic Review, which is currently being conducted by the AHRQ’s Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

DATES: Submission Deadline on or before January 3, 2019.

ADDRESSES: Email submissions: epc@ahrq.hhs.gov.

Print submissions:

Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.

Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Jenaee Bennis, Telephone: 301–427–1496 or Email: epc@ahrq.hhs.gov.

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to conduct a review of the scientific information for Interventions for Substance Use Disorders in Adolescents: A Systematic Review. AHRQ is conducting this systematic review pursuant to Section 902(a) of the Public Health Service Act, 42 U.S.C. 299a(a).

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on Interventions for Substance Use Disorders in Adolescents: A Systematic Review, including those that describe adverse events. The entire research protocol, including the key questions, is also available online at: https://effectivehealthcare.ahrq.gov/topics/substance-use-disorders-adolescents/protocol.

This is to notify the public that the EPC Program would find the following information on Interventions for Substance Use Disorders in Adolescents: A Systematic Review helpful:

• A list of completed studies that your organization has sponsored for this indication. In the list, please indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.

• For completed studies that do not have results on ClinicalTrials.gov, please provide a summary, including the following elements: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.

• A list of ongoing studies that your organization has sponsored for this indication. In the list, please provide the ClinicalTrials.gov trial number or if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

• Description of whether the above studies constitute ALL Phase II and above clinical trials sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution will be very beneficial to the EPC Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ’s EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: https://www.effectivehealthcare.ahrq.gov/email-updates.

The systematic review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.

The Key Questions

KQ 1: What are the effects of behavioral, pharmacologic, and combined interventions compared with placebo or no active treatment for substance use disorders and problematic substance use 1 in adolescents to achieve abstinence, reduce quantity and frequency of use, improve functional outcomes, and reduce substance-related harms?

a. How do benefits and adverse outcomes of interventions vary by subpopulations? 2

1 Substances considered: Alcohol, cannabis, opioids, sedatives/hypnotics/anxiolytics, stimulants, inhalants and hallucinogens. Tobacco is excluded.

2 Subpopulations considered: Psychiatric comorbidities, age (early, middle and late

Continued
b. How do benefits and adverse outcomes of interventions vary by intervention characteristics?3

KQ 2: What are the comparative effects of active interventions for substance use disorders and problematic substance use 1 in adolescents to achieve abstinence, reduce quantity and frequency of use, improve functional outcomes, and reduce harms?

a. How do comparative benefits and adverse outcomes of interventions vary by subpopulations?2

b. How do comparative benefits and adverse outcomes of interventions vary by intervention characteristics?3

PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, Settings)

Population (all KQs)

- Age: Adolescents (12–20 years inclusive)
  - Exclude if >20 percent of study sample (or identifiable subgroup) is <12 or >20 years, combined
- SUD or problematic use of:
  - Alcohol
  - Exclude primary studies of treatment of alcohol use disorder/problematic alcohol use in the college setting (we will include existing systematic reviews)
- Cannabis
- Opioids
- Nonmedical prescription drug use (codeine, hydrocodone, oxycodone)
- Illicit (e.g., heroin, illicit synthetics)
- Sedatives, hypnotics, or anxiolytics (e.g., benzodiazepines, carbamates, barbiturates, methaqualone)
- Stimulants
- Nonmedical prescription drug use (e.g., methylphenidate)
- Illicit (e.g., cocaine, methamphetamine)
- Inhalants
- Hallucinogens (e.g., phencyclidine, ketamine, MDMA, LSD)
- Unspecified or polysubstance use
- Exclude if predominately tobacco/nicotine use
- Exclude tobacco/nicotine use disorder or problematic tobacco/nicotine use
- Exclude limited (or experimental) substance use that has not been deemed to be at least “problematic”
- Subpopulations of interest (not necessary for eligibility)
  - Psychiatric comorbidities

Interventions

- Behavioral health treatments (major intervention models are indicated by arrowhead bullets, in bold)
  - Family Therapies
    - Family behavioral therapy (FBT)
    - Family systems therapy (FST)
    - Brief strategic family therapy (BSFT)
    - Functional family therapy (FFT)
    - Ecological family therapy
    - Multidimensional family therapy (MDFT)
    - Ecologically based family therapy (EBFT)
    - Family systems network (FSN)
    - Educational family therapy
    - Multi-systemic therapy (MST)
  - Cognitive Behavioral Therapy (CBT)
    - Adolescent community reinforcement approach (ACRA)
    - Dialectical behavior therapy
    - Cognitive therapy
  - Contingency Management
  - Motivational Interviewing/Motivation Enhancement Therapy
  - Multi-Component Interventions
  - Psychoeducation
  - Treatment as Usual (does not meet criteria for any of the above categories)
  - Integrated Interventions for substance use and a co-occurring disorder
  - Other
  - Culturally sensitive interventions
  - Recovery Support
    - 12-step programs
  - Peer-based and/or peer supports
  - Assertive continuing care (ACC) Exclusive (primary (universal) and secondary preventive interventions.
  - Exclusive interventions used in population that do not aim to reduce substance use (e.g., needle exchange).

- Pharmacologic Interventions
  - Exclude medications being used to treat overdose (e.g., naloxone)
  - Exclude pharmacologic management of acute withdrawal symptoms
  - Medications to reduce and/or eliminate substance use and to prevent relapse (See Appendix B for details of FDA approvals)
  - Alcohol
  - Gabapentin
  - Naltrexone
  - Acamprosate
  - Disulfiram
  - Topiramate
  - Ondansetron
  - Cannabis
  - N-acetylcysteine (NAC)
  - Opioids
  - Methadone
  - Buprenorphine
  - Buprenorphine/Naloxone
  - Naltrexone
  - Medications to treat co-occurring psychiatric disorders in patients in patients with concurrent problematic substance use or SUD.

Comparators

KQ 1

- No active treatment
- Wait list
- Placebo (for medications)
- Usual care (if not a clearly defined behavioral intervention)

KQ 2

- Active interventions (we will evaluate other comparisons if the evidence allows)
  - Pharmacologic plus behavioral vs. behavioral or pharmacologic alone
  - Between major behavioral intervention models (e.g., family therapy, cognitive behavioral therapy)
  - Multicomponent interventions vs. single behavioral intervention model

Outcomes

- Abstinence
  - Urine drug test results (from substance identified on admission to treatment, abstinence from all substances, duration of abstinence)
- Quantity, Frequency, or Severity of Use (of primary substance identified on entry to treatment and other substances)
  - Days of use/abstinence over
Functional Outcomes
- School performance and educational attainment
- Attendance
- Grades/academic performance
- Graduation rates
- Entering higher education (including trade schools)
- Social relationships
- Family functioning
- Peer relationships

Harmful Consequences Associated With SUD
- Mental health outcomes
  - Suicidal ideation and behavior
- Physical health outcomes
  - Mortality
  - All-cause
  - Drug-related, including fatal
  - Overdose
  - Morbidity
  - Injuries (non-fatal)
  - Infections
  - HIV
  - Hepatitis C
- Other sexually transmitted infections
- Legal outcomes
  - Arrests
- Drunk or impaired driving
- Contact with juvenile justice system

Adverse Effects of Intervention(s)
- Side effects of pharmacologic interventions
- Loss of privacy/confidentiality
- Stigmatization/discrimination
- Iatrogenic effects of group therapy due to peer deviance
- Other reported adverse effects ascribed to interventions

Study Designs and Information Sources
- Published, peer reviewed articles and data from clinicaltrials.gov
  - Randomized controlled trials (including cross-over trials)
  - N ≥ 10 participants per study group
  - Large nonrandomized comparative studies with longitudinal follow-up
  - N ≥ 100 participants per study group
- Must report multiple regression, other adjustment, matching, propensity scoring, or other method to account for confounding.
- Single arm pharmacologic studies with at least 200 participants and longitudinal follow-up (to identify side-effects of medications)
- We will summarize information from existing systematic reviews specific to treatment of alcohol SUD on college campuses
- SR eligible if inclusion criteria for individual studies consistent with our PICOTS criteria for individual studies.

Exclusions
- Case-control studies
- Cross-sectional studies
- Single-arm studies of behavioral interventions
- Conference abstracts letters, and other non-peer-reviewed reports

Timing
- Any duration of treatment
- Duration of follow-up of at least a month (but must be longitudinal with separation in time between intervention and outcomes)

Setting
- Any setting, including (but not limited to) primary care, school, outpatient, emergency department, in-patient, intensive outpatient, partial hospitalization, intensive inpatient/residential, juvenile justice
- Exclude: laboratory-based assessments.

Francis D. Chesley, Jr.,
Acting Deputy Director.
[FR Doc. 2018–26315 Filed 12–3–18; 8:45 am]
BILLING CODE 4160–90–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS–6063–N4]
Medicare Program; Extension of Prior Authorization for Repetitive Scheduled Non-Emergent Ambulance Transports
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.

SUMMARY: This notice announces a 1-year extension of the Medicare Prior Authorization Model for Repetitive Scheduled Non-Emergent Ambulance Transport. The extension of this model is applicable to the following states and the District of Columbia: Delaware, Maryland, New Jersey, North Carolina, Pennsylvania, South Carolina, Virginia, and West Virginia.

DATES: This extension begins on December 2, 2018 and ends on December 1, 2019.

FOR FURTHER INFORMATION CONTACT: Angela Gaston, (410) 786–7409. Questions regarding the Medicare Prior Authorization Model Extension for Repetitive Scheduled Non-Emergent Ambulance Transport should be sent to AmbulancePA@cms.hhs.gov.

SUPPLEMENTARY INFORMATION:
I. Background
Medicare may cover ambulance services, including air ambulance (fixed-wing and rotary-wing) services, if the ambulance service is furnished to a beneficiary whose medical condition is